Inhibrx Biosciences Inc (INBX): Next-Year EPS Estimate 29.29%
As of 2026-06-11, Inhibrx Biosciences Inc (INBX) has a next-year EPS growth estimate of 29.29%.
On 2026-05-17, analyst consensus for INBX's next-year EPS growth shifted from 28.35% to 29.29% — a positive change of 0.94 percentage points. The revised estimate has been sustained across 20 subsequent trading sessions. Current-year growth is projected at -2.16%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 29.29%
- EPS growth this year
- -2.16%
- EPS next quarter (est)
- -$2.28
- Last price
- $93.54
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 29.29% | -2.16% | -$2.28 | $93.54 |
| 2026-06-10 | 29.29% | -2.16% | -$2.28 | $89.47 |
| 2026-06-09 | 29.29% | -2.16% | -$2.28 | $89.10 |
| 2026-06-08 | 29.29% | -2.16% | -$2.28 | $89.13 |
| 2026-06-07 | 29.29% | -2.16% | -$2.28 | $87.01 |
| 2026-06-04 | 29.29% | -2.16% | -$2.28 | $91.25 |
| 2026-06-03 | 29.29% | -2.16% | -$2.28 | $95.22 |
| 2026-06-02 | 29.29% | -2.16% | -$2.28 | $93.63 |
| 2026-06-01 | 29.29% | -2.16% | -$2.28 | $99.29 |
| 2026-05-31 | 29.29% | -2.16% | -$2.28 | $104.01 |
| 2026-05-28 | 29.29% | -2.16% | -$2.28 | $103.98 |
| 2026-05-27 | 29.29% | -2.16% | -$2.28 | $103.00 |
| 2026-05-26 | 29.29% | -2.16% | -$2.28 | $106.85 |
| 2026-05-25 | 29.29% | -2.16% | -$2.28 | $101.32 |
| 2026-05-24 | 29.29% | -2.16% | -$2.28 | $101.32 |
| 2026-05-21 | 29.29% | -2.16% | -$2.28 | $110.57 |
| 2026-05-20 | 29.29% | -2.16% | -$2.28 | $110.01 |
| 2026-05-19 | 29.29% | -2.16% | -$2.28 | $109.51 |
| 2026-05-18 | 29.29% | -2.16% | -$2.28 | $105.80 |
| 2026-05-17 | 29.29% | -2.16% | -$2.28 | $108.64 |
| 2026-05-14 | 28.35% | 13.38% | -$1.68 | $116.16 |
| 2026-05-13 | 28.35% | 13.38% | -$1.68 | $112.76 |
| 2026-05-12 | 28.35% | 13.38% | -$1.68 | $108.65 |
| 2026-05-11 | 28.35% | 13.38% | -$1.68 | $127.58 |
| 2026-05-10 | 28.35% | 13.38% | -$1.68 | $134.35 |
| 2026-05-07 | 28.35% | 13.38% | -$1.68 | $124.52 |
| 2026-05-06 | 28.35% | 13.38% | -$1.68 | $141.84 |
| 2026-05-05 | 28.35% | 13.38% | -$1.68 | $128.12 |
| 2026-05-04 | 28.35% | 13.38% | -$1.68 | $127.95 |
| 2026-05-03 | 28.35% | 13.38% | -$1.68 | $128.79 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Inhibrx Biosciences Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Inhibrx Biosciences Inc (INBX) has a next-year EPS growth estimate of 29.29%, based on analyst consensus.
When was the latest EPS estimate revision for INBX?▾
The most recent revision occurred on 2026-05-17, when analysts adjusted the next-year EPS growth estimate from 28.35% to 29.29%.
What sector and industry does Inhibrx Biosciences Inc belong to?▾
Inhibrx Biosciences Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. INBX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Inhibrx Biosciences Inc (INBX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports